Notice: This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends ELTX vs. MBIO, ACIU, NATR, VNDA, HRTX, AMLX, NGNE, ATAI, DMAC, and URGNShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Mustang Bio (MBIO), AC Immune (ACIU), Nature's Sunshine Products (NATR), Vanda Pharmaceuticals (VNDA), Heron Therapeutics (HRTX), Amylyx Pharmaceuticals (AMLX), Neurogene (NGNE), Atai Life Sciences (ATAI), DiaMedica Therapeutics (DMAC), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical preparations" industry. Elicio Therapeutics vs. Mustang Bio AC Immune Nature's Sunshine Products Vanda Pharmaceuticals Heron Therapeutics Amylyx Pharmaceuticals Neurogene Atai Life Sciences DiaMedica Therapeutics UroGen Pharma Elicio Therapeutics (NASDAQ:ELTX) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings. Does the media prefer ELTX or MBIO? In the previous week, Elicio Therapeutics and Elicio Therapeutics both had 5 articles in the media. Mustang Bio's average media sentiment score of 0.62 beat Elicio Therapeutics' score of 0.00 indicating that Mustang Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mustang Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ELTX or MBIO? Elicio Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Is ELTX or MBIO more profitable? Mustang Bio's return on equity of 0.00% beat Elicio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Elicio TherapeuticsN/A -555.45% -177.34% Mustang Bio N/A N/A -172.89% Do analysts prefer ELTX or MBIO? Elicio Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 3.73%. Mustang Bio has a consensus target price of $100.00, indicating a potential upside of 2,032.20%. Given Mustang Bio's stronger consensus rating and higher possible upside, analysts plainly believe Mustang Bio is more favorable than Elicio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elicio Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in ELTX or MBIO? 35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 28.7% of Elicio Therapeutics shares are owned by insiders. Comparatively, 0.6% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable earnings & valuation, ELTX or MBIO? Elicio Therapeutics has higher revenue and earnings than Mustang Bio. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElicio Therapeutics$2.30M45.22-$35.19M-$6.95-1.39Mustang BioN/AN/A-$51.60M-$78.00-0.06 Does the MarketBeat Community favor ELTX or MBIO? Mustang Bio received 163 more outperform votes than Elicio Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Elicio Therapeutics an outperform vote while only 64.26% of users gave Mustang Bio an outperform vote. CompanyUnderperformOutperformElicio TherapeuticsOutperform Votes685.71% Underperform Votes114.29%Mustang BioOutperform Votes16964.26% Underperform Votes9435.74% SummaryMustang Bio beats Elicio Therapeutics on 7 of the 13 factors compared between the two stocks. Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.61M$6.92B$5.61B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E RatioN/A10.1189.6917.66Price / Sales45.22351.361,219.4081.09Price / CashN/A65.4844.3437.71Price / Book7.145.335.134.73Net Income-$35.19M$157.56M$118.85M$225.42M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics0.3714 of 5 stars$9.64+13.4%$10.00+3.7%+82.8%$80.61M$2.30M0.00N/AShort Interest ↑News CoverageHigh Trading VolumeMBIOMustang Bio2.991 of 5 stars$5.55-5.6%$100.00+1,701.8%-93.3%$265.18MN/A-3.56100Short Interest ↓Gap DownACIUAC Immune2.5134 of 5 stars$2.68+1.5%$12.00+347.8%-17.9%$265.16M$40.97M-5.83140Positive NewsNATRNature's Sunshine Products3.3251 of 5 stars$14.27+0.1%$19.00+33.1%-16.0%$263.65M$445.10M16.22850News CoveragePositive NewsVNDAVanda Pharmaceuticals4.3154 of 5 stars$4.36-1.8%$15.50+255.5%+19.2%$254.23M$192.64M-15.57290Upcoming EarningsAnalyst ForecastHRTXHeron Therapeutics3.7696 of 5 stars$1.63+3.8%$5.67+247.6%-34.0%$247.92M$127.04M-9.06300Analyst DowngradeNews CoverageAMLXAmylyx Pharmaceuticals3.129 of 5 stars$3.60+2.9%$7.33+103.7%-78.1%$246.78M$380.79M-0.94200Short Interest ↑NGNENeurogene3.2226 of 5 stars$16.60-5.8%$60.83+266.5%-51.5%$246.51MN/A0.0090ATAIAtai Life Sciences2.4419 of 5 stars$1.46+5.0%$9.00+516.4%-23.5%$244.99M$310,000.00-1.8080Analyst ForecastGap UpDMACDiaMedica Therapeutics1.5104 of 5 stars$5.71+0.7%$7.00+22.6%+123.1%$244.16MN/A-10.2020Short Interest ↑Negative NewsGap DownHigh Trading VolumeURGNUroGen Pharma3.9412 of 5 stars$10.27-2.4%$43.70+325.5%-31.7%$240.87M$89.36M-3.26200 Related Companies and Tools Related Companies MBIO Competitors ACIU Competitors NATR Competitors VNDA Competitors HRTX Competitors AMLX Competitors NGNE Competitors ATAI Competitors DMAC Competitors URGN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELTX) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELTX Stock Alerts